BillionToOne, Inc. (BLLN)
| Market Cap | 3.57B |
| Revenue (ttm) | 305.11M |
| Net Income (ttm) | 2.92M |
| Shares Out | 45.99M |
| EPS (ttm) | 0.14 |
| PE Ratio | 553.79 |
| Forward PE | 162.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 271,891 |
| Open | 82.09 |
| Previous Close | 81.76 |
| Day's Range | 75.96 - 82.25 |
| 52-Week Range | 61.96 - 138.70 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 126.71 (+63.43%) |
| Earnings Date | May 6, 2026 |
About BLLN
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for BLLN stock is "Buy." The 12-month stock price target is $126.71, which is an increase of 63.43% from the latest price.
News
BillionToOne Appoints Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development, Oncology
Renowned physician executive and clinician-scientist joins BillionToOne to advance oncology medical strategy MENLO PARK, Calif., April 2, 2026 /PRNewswire/ -- BillionToOne , Inc. (Nasdaq: BLLN), a nex...
BillionToOne Earnings Call Transcript: Q4 2025
Delivered 100% revenue growth in 2025, achieving GAAP profitability and strong cash flow. Q4 revenue rose 113% year-over-year, driven by innovation in prenatal and oncology, expanded payer coverage, and record gross margins. 2026 guidance raised to $430–$445 million.
BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance
MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are ...
BillionToOne to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
MENLO PARK, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are a...
BillionToOne Expands Northstar Platform with Launch of Two New Add-On Liquid Biopsy Applications for Northstar Select®
Northstar PGx™ and Northstar Select CH™ extend clinical insight and utility of Northstar Select® all from the same blood-draw MENLO PARK, Calif., Feb. 10, 2026 /PRNewswire/ -- BillionToOne , Inc. (Na...
BillionToOne Announces Dual Launch of UNITY Expanded Red Blood Cell and Platelet Fetal Antigen NIPTs, Extending Its Leadership In Setting the New Standard in Prenatal Care
BillionToOne Expands Its Leadership in Hemolytic Disease of the Fetus and Newborn (HDFN) and Extends Fetal Antigen Testing to Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) MENLO PARK, Calif.,...
BillionToOne Announces Collaboration with Epic to Expand Prenatal and Oncology Testing Across Healthcare
Integration enables seamless ordering and results delivery within Epic for UNITY Complete® and Northstar® tests, creating a better patient and provider experience MENLO PARK, Calif., Jan. 15, 2026 /PR...
BillionToOne Transcript: 44th Annual J.P. Morgan Healthcare Conference
A single molecule sequencing platform is driving rapid growth, high margins, and GAAP profitability, with strong adoption in prenatal and oncology diagnostics. Market share is expanding through superior technology, efficient operations, and robust clinical data. Clinical and commercial momentum support raised revenue guidance for 2026.
BillionToOne Provides Guidance for 2026
MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are a...
BillionToOne Announces Selection of Northstar Select® as the new liquid biopsy test for LC-SCRUM-TRY clinical study at National Cancer Center Hospital East
Ultra-sensitive liquid biopsy is expanding precision medicine access for patients in Japan with treatment-resistant non-small cell lung cancer (NSCLC) MENLO PARK, Calif., Jan. 6, 2026 /PRNewswire/ -- ...
BillionToOne to Participate in the 44th Annual J.P. Morgan Healthcare Conference
MENLO PARK, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are a...
BillionToOne Earnings Call Transcript: Q3 2025
Achieved 117% year-over-year revenue growth and 70% gross margin in Q3 2025, with strong performance in both prenatal and oncology segments. Raised $314 million in IPO, issued 2025 guidance for 92–96% revenue growth, and expects continued profitability.
BillionToOne Appoints Anthony Pagano to Board of Directors as Audit Committee Chair
MENLO PARK, Calif. , Dec. 9, 2025 /PRNewswire/ – BillionToOne , Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are acces...
BillionToOne Reports Third Quarter 2025 Results
MENLO PARK, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are a...
BillionToOne to Report Third Quarter 2025 Financial Results on December 9, 2025
MENLO PARK, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all...
Analysts See Big Upside For Newly Listed Molecular Diagnostic Firm BillionToOne After Standout IPO Rally
BillionToOne, Inc., (NASDAQ: BLLN) recently completed an upsized initial public offering, or IPO, of 5.23 million shares at $60 each, raising roughly $314 million.
BillionToOne wins upbeat coverage as analysts flag growth in prenatal, cancer tests
Wall Street analysts, who acted as lead underwriters for BillionToOne's Nasdaq debut last month, began coverage of the diagnostics firm on Monday with broadly upbeat views, pointing to its advanced te...
Gunderson Dettmer Represents Long-Time Client BillionToOne in its Upsized $273.1 Million Initial Public Offering
REDWOOD CITY, Calif. , Nov. 6, 2025 /PRNewswire/ -- Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, a leading law firm in technology and life sciences transactions, represented long-tim...
BillionToOne valued at $4.4 billion as shares surge in blockbuster Nasdaq debut
Shares of BillionToOne rose 66.67% in their Nasdaq debut on Thursday, valuing the molecular diagnostics firm at $4.4 billion.
Molecular diagnostics firm BillionToOne raises $273 million in US IPO
Molecular diagnostics firm BillionToOne raised $273.1 million in its U.S. initial public offering on Wednesday, pricing its shares above its marketed range.
BillionToOne Announces Pricing of Upsized Initial Public Offering
MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (Nasdaq: BLLN), a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all...
BillionToOne Announces Launch of Initial Public Offering Roadshow
MENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announc...
BillionToOne targets over $2 billion valuation in US IPO
Molecular diagnostics firm BillionToOne said on Friday it was aiming at a valuation of up to $2.42 billion in its U.S. initial public offering.
Molecular diagnostics firm BillionToOne files for US IPO
BillionToOne filed for an initial public offering in the United States on Tuesday.
BillionToOne IPO Registration Document (S-1)
BillionToOne has filed to go public with an IPO on the NASDAQ.